KALA BIO Q2 2025 Earnings Results & Report

KALA BIO EPS Results

• Actual EPS: -$85.50
• Consensus EPS: -$91.00
• Beat/Miss: Beat by +$5.50
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 5 quarters

KALA BIO Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

KALA BIO (NASDAQ:KALA), formerly known as Kala Pharmaceuticals, is a clinical-stage biotechnology company focused on developing treatments for severe diseases affecting the eye. The company’s research has centered on therapies designed to address conditions for which available treatment options may be limited or inadequate.

KALA BIO’s lead investigational product has been KPI-012, an ophthalmic biologic being studied for rare corneal conditions, including persistent corneal epithelial defects. The company has also developed therapies using its proprietary mucus-penetrating particle technology, which is intended to improve the delivery of medicines to ocular tissues.

Historically, the company developed and commercialized EYSUVIS, a corticosteroid eye drop approved in the United States for the short-term treatment of dry-eye disease, and XIPERE, an injectable treatment for macular edema associated with uveitis. KALA BIO is headquartered in the United States and has primarily focused its development and regulatory activities on the U.S. ophthalmology market.